knowledge -WSS

knowledge

author：knowledge 2025-09-06 03:54:22 - browse：72683

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

hotspot

focus

WSS

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Pfizer is about to make a big push in cancer. Will investors listen?

What STAT readers think about the FDA and patient advocacy

Ohio train derailment: Experts on toxic chemical risks

Redefining sustainability for the pharmaceutical industry

Elisabeth Bik tackles the widespread issue of research misconduct

knowledge

knowledge

focus

As demand for Covid shots wanes, Moderna seeks its next success

Medicare drug price negotiation hasn't dried up venture capital

After affirmative action ruling, medical educators look to 'holistic review'

Color Health wants to make cancer screenings convenient

In Memoriam: Notable people who died in 2023

Using force crossed my mind when examining a defiant young patient

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Redefining sustainability for the pharmaceutical industry

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

leisure time

Pfizer is about to make a big push in cancer. Will investors listen?

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Drinking less cuts risk of oral cavity, esophageal cancer: Report

What STAT readers think about the FDA and patient advocacy

hotspot

focus

knowledge

entertainment